SeaStar Medical Announces 2026 Milestones

Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer baseAdvance SeaStar Medical’s ...
Seeking Alpha

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac ...

DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference

Additionally, SeaStar Medical’s management team will be meeting with investors in San Francisco during the 44 th Annual J.P. Morgan Healthcare Conference from January 12-14, 2026.
Benzinga.com

What's Going On With Medical Devices Focused SeaStar Medical Stock Today?

SeaStar Medical Holding Corporation (NASDAQ:ICU) shares are trading higher on Thursday, on continued strength after the company received FDA Breakthrough Device Designation for its cell-directed ...
Nasdaq

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...
Seeking Alpha

SeaStar Medical gets Approvable Letter for SCD-PED device

SeaStar Medical (NASDAQ:ICU) said it has received an Approvable Letter from the FDA for its Selective Cytopheretic Device Pediatric, or SCD-PED, for use in children with acute kidney injury and sepsis ...